Mast cell activation and nutritional disorders in patients with hypermobility

Curr Opin Gastroenterol. 2024 May 1;40(3):225-232. doi: 10.1097/MOG.0000000000001008. Epub 2024 Feb 23.

Abstract

Purpose of review: Individuals with joint hypermobility disorders are increasingly referred to gastroenterology services for support with the investigation and management of gastrointestinal complaints. Individuals can present with a myriad of complex coexisting diagnoses, the inter-relationship of which is unclear. This review discusses the proposed association between hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorder (HSD) with disorders of mast cell activation and provides an overview of gastrointestinal symptoms and nutritional outcomes in this patient cohort.

Recent findings: It is unclear whether a true association between hEDS/HSD and mast cell activation disorders exists. There is a high prevalence of nonspecific gastrointestinal symptoms in individuals with hEDS/HSD and patients may be at risk of macro-nutrient and micro-nutrient deficiencies, although the current evidence base is limited.

Summary: We advocate a pragmatic approach to the investigation and management of gastrointestinal symptoms in patients with hEDS/HSD. This centres on excluding organic pathology, discussing the overlap with disorders of gut-brain interactions, trialling evidence-based therapies targeting individual symptoms, and supporting nutritional deficiencies where present via the least invasive approach. Engagement with a broad multidisciplinary team is also important to support the holistic needs of this patient cohort.

Publication types

  • Review

MeSH terms

  • Ehlers-Danlos Syndrome* / complications
  • Ehlers-Danlos Syndrome* / diagnosis
  • Ehlers-Danlos Syndrome* / therapy
  • Humans
  • Joint Instability* / complications
  • Joint Instability* / diagnosis
  • Joint Instability* / therapy
  • Malnutrition* / complications
  • Malnutrition* / therapy
  • Mast Cells / pathology
  • Nutrition Disorders* / complications

Supplementary concepts

  • Ehlers-Danlos syndrome type 3